Published on September 8, 2014

Indian Pharma Sector internationally over past few years has been living through an exponential growth and stability and the Indian pharmaceutical companies in semi-regulated and regulated markets have capitalised on export opportunities, as per the sources. Exports of Pharma from Indian from the year 2006 to 2012 have grown at a 20% CAGR in excess. According to the researched report, at present India is noted as the third largest exporter of Active Pharmaceuticals Ingredients (APIs).

India’s exposure to Japan which is the second largest pharma market in the world is a sheer 1%, moreover Japan is also noted as one of the most difficult pharma markets to access. As per the sources, to get a foot in the door to lucrative Japan many Indian generic drug makers are exploring all options, however it is to crack USD 111 billion drug industries is quite difficult. According to the industry experts, major drug pharma industry such as Sun Pharma, Glenmark Pharmaceuticals, Lupin, Aurobindo Pharma, Dr Reddy's Laboratories and Sami Labs are making efforts to increase their business with Japan.

According to the market players, the much-awaited review of the India-Japan comprehensive economic partnership agreement (Cepa), the issue of giving Indian drug companies more access to the Japanese pharmaceutical market remains wedged. However with the visit of Indian Prime Minister Narendra Modi to Japan from 30th August to 3rd September, 2014 was projected to yield a few comprehensive results for traders and business community at large of India.

As per the industry experts, in near future most of the analysts are bullish on medium to long term prospects of Glenmark Pharmaceuticals, in spite of bleak outlook. Furthermore as per the researched report Indian pharma are expected to bring in an estimated USD 25 billion by the end of 2014.